National Rules for Drug-Drug Interactions: Are They Appropriate for Tertiary Hospitals?

被引:2
|
作者
Cho, Insook [1 ,2 ,3 ]
Lee, Jae-Ho [2 ,4 ,5 ,6 ]
Choi, Jinwook [8 ]
Hwang, Hee [7 ]
Bates, David W. [2 ,3 ,8 ]
机构
[1] Inha Univ, Dept Nursing, Inchon, South Korea
[2] Brigham & Womens Hosp, Div Gen Internal Med, Ctr Patient Safety Res & Practice, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA USA
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Emergency Med, 88 Olymp Ro 43 Gil, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Biomed Informat, Seoul, South Korea
[6] Seoul Natl Univ Hosp, Seoul, South Korea
[7] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[8] Partners Healthcare Syst, Wellesley, MA USA
基金
新加坡国家研究基金会; 美国医疗保健研究与质量局;
关键词
Medication Safety; Drug-Drug Interactions; Prescription Alerts; Overrides; Alert Fatigue; CLINICAL DECISION-SUPPORT; ELECTRONIC HEALTH RECORDS; SYSTEM; SEVERITY; ALERTS;
D O I
10.3346/jkms.2016.31.12.1887
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The application of appropriate rules for drug-drug interactions (DDIs) could substantially reduce the number of adverse drug events. However, current implementations of such rules in tertiary hospitals are problematic as physicians are receiving too many alerts, causing high override rates and alert fatigue. We investigated the potential impact of Korean national DDI rules in a drug utilization review program in terms of their severity coverage and the clinical efficiency of how physicians respond to them. Using lists of high-priority DDIs developed with the support of the U.S. government, we evaluated 706 contraindicated DDI pairs released in May 2015. We evaluated clinical log data from one tertiary hospital and prescription data from two other tertiary hospitals. The measured parameters were national DDI rule coverage for high-priority DDIs, alert override rate, and number of prescription pairs. The coverage rates of national DDI rules were 80% and 3.0% at the class and drug levels, respectively. The analysis of the system log data showed an overall override rate of 79.6%. Only 0.3% of all of the alerts (n = 66) were high-priority DDI rules. These showed a lower override rate of 51.5%, which was much lower than for the overall DDI rules. We also found 342 and 80 unmatched high-priority DDI pairs which were absent in national rules in inpatient orders from the other two hospitals. The national DDI rules are not complete in terms of their coverage of severe DDIs. They also lack clinical efficiency in tertiary settings, suggesting improved systematic approaches are needed.
引用
收藏
页码:1887 / 1896
页数:10
相关论文
共 50 条
  • [21] Drug-drug interactions.: An update
    Morales-Olivas, Francisco J.
    Estan, Luis
    MEDICINA CLINICA, 2006, 127 (07): : 269 - 275
  • [22] Drug-Drug Interactions in Headache Medicine
    Ansari, Hossein
    Ziad, Sanaz
    HEADACHE, 2016, 56 (07): : 1241 - 1248
  • [23] Evaluation of drug-drug interactions with fesoterodine
    Malhotra, Bimal
    Sachse, Richard
    Wood, Nolan
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (06) : 551 - 560
  • [24] Contradictions in Contraindications for Drug-Drug Interactions
    Shah, Vishal S.
    Weber, Robert J.
    Nahata, Milap C.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (03) : 409 - 411
  • [25] Knowledge and information sources of potential drug-drug interactions of healthcare professionals among Buraydah Hospitals
    Abougalambou, Salwa Selim Ibrahim
    Alenezi, Tief Naif
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2023, 16 (01)
  • [26] Measuring drug similarity using drug-drug interactions
    Lv, Ji
    Liu, Guixia
    Ju, Yuan
    Huang, Houhou
    Sun, Ying
    QUANTITATIVE BIOLOGY, 2024, 12 (02) : 164 - 172
  • [27] Renal drug transporters and their significance in drug-drug interactions
    Yin, Jia
    Wang, Joanne
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 363 - 373
  • [28] Clinically relevant potential drug-drug interactions in intensive care patients: A large retrospective observational multicenter study
    Bakker, Tinka
    Abu-Hanna, Ameen
    Dongelmans, Dave A.
    Vermeijden, Wytze J.
    Bosman, Rob J.
    Lange, Dylan W. de
    Klopotowska, Joanna E.
    Keizer, Nicolette F. de
    Hendriks, S.
    Cate, J. ten
    Schutte, P. F.
    Balen, D. van
    Duyvendak, M.
    Karakus, A.
    Sigtermans, M.
    Kuck, E. M.
    Hunfeld, N. G. M.
    Sijs, H. van der
    Feiter, P. W. de
    Wils, E. -J.
    Spronk, P. E.
    Kan, H. J. M. van
    Steen, M. S. van der
    Purmer, I. M.
    Bosma, B. E.
    Kieft, H.
    Marum, R. J. van
    Jonge, E. de
    Beishuizen, A.
    Movig, K.
    Mulder, F.
    Franssen, E. J. F.
    Bergh, W. M. van den
    Bult, W.
    Hoeksema, M.
    Wesselink, E.
    JOURNAL OF CRITICAL CARE, 2021, 62 : 124 - 130
  • [29] An Evaluation of Tertiary Drug Resources' Consistency Regarding Drug-Drug Interactions Between Tricyclic Antidepressants and Herbal Supplements
    Engel, Elizabeth
    Friedt, Carter T. T.
    Reinert, Justin P. P.
    JOURNAL OF PHARMACY TECHNOLOGY, 2023, 39 (02) : 62 - 67
  • [30] Potential drug-drug interactions and associated factors among admitted patients with psychiatric disorders at selected hospitals in Northwest Ethiopia
    Ephrem Mebratu Dagnew
    Asrat Elias Ergena
    Samuel Agegnew Wondm
    Ashenafi Kibret Sendekie
    BMC Pharmacology and Toxicology, 23